Noveome Biotherapeutics, Inc. and SipNose, Ltd. Announce Commercial License Agreement for SipNose Cribriform Targeted Device
Retrieved on:
Tuesday, June 1, 2021
Biotechnology, Medical devices, Other Health, Health, Pharmaceutical, Health sciences, Clinical medicine, Dosage forms, Nasal administration, Yokneam, Cribriform, Glaucoma, Health, ST266, Noveome Biotherapeutics, Inc., SipNose Cribriform Targeted Device, SipNose Ltd., ST266, NOVEOME BIOTHERAPEUTICS, INC., SIPNOSE CRIBRIFORM TARGETED DEVICE, SIPNOSE LTD.
Noveome Biotherapeutics, Inc. , Pittsburgh, PA, and SipNose, Ltd., Yokneam, Israel, announced today that they have entered into a Commercial License Agreement (Agreement) for Noveomes use of SipNoses proprietary intranasal Cribriform Targeted Device (CT6) to deliver Noveomes first-of-its-kind biologic, ST266, to the central nervous system (CNS).
Key Points:
- Noveome Biotherapeutics, Inc. , Pittsburgh, PA, and SipNose, Ltd., Yokneam, Israel, announced today that they have entered into a Commercial License Agreement (Agreement) for Noveomes use of SipNoses proprietary intranasal Cribriform Targeted Device (CT6) to deliver Noveomes first-of-its-kind biologic, ST266, to the central nervous system (CNS).
- Noveome and SipNose have established a great working relationship which has enabled a successful collaboration, said William J.
- Noveome recently closed enrollment and completed the treatment phase of its Phase 1 safety study using the SipNose device to administer ST266 to Glaucoma Suspect patients.
- Based in Israel, SipNose is a clinical stage nasal delivery company that has developed an innovative Cribriform Targeted Device for non-invasive delivery of pharmaceuticals.